Donavon McConn, PhD is an accomplished biotechnology executive leading Ostentus
Therapeutics as Chief Executive Officer. With nearly three decades of industry experience, he leverages his extensive background to drive Ostentus’ platform-based approach to innovative therapeutics. His strategic leadership at XinThera was instrumental in advancing its scientific program—a key factor in its acquisition by Gilead in 2023. Dr. McConn’s experience spans critical stages of drug development, from early-stage target validation and IND-enabling studies to advancing assets into clinical development, positioning Ostentus Therapeutics to seize emerging opportunities in the biotech sector.

Dr. McConn earned his BS in Physiology and Biochemistry from UC Davis and his PhD in
Pharmaceutics from the University of Washington. His career includes key roles at esteemed organizations such as GlaxoSmithKline, Theravance, and Takeda Ventures, where he achieved significant industry milestones. Dr. McConn concurrently serves as a member of the executive team of Lotura Therapeutics, Inc., an innovative peptide therapeutics company of which he is the founder.